Loading...
Loading...
- Quest Diagnostics Incorporated DGX has posted a better-than-expected Q3 adjusted EPS of $3.96, down 7.9% Y/Y, beating the consensus estimate of $2.87.
- Sales came in at $2.77 billion, a marginal decline of 0.4% Y/Y, higher than the Wall Street estimate of $2.45 billion.
- "In late summer, we experienced some softness in the base business across the country but saw an overall rebound in September," said Steve Rusckowski, Chairman, CEO, and President.
- Quest witnessed rising labor costs and inflationary pressures. Adjusted operating margin compressed to 25.0% from 29.8% a year ago.
- Outlook: On higher than anticipated COVID-19 volumes, Quest forecasts FY21 sales of $10.45 billion - $10.60 billion ($9.54 billion - $9.79 billion earlier), higher than the consensus of $10 billion.
- It also estimated annual adjusted EPS of $13.50 - $13.90, compared to previous guidance of $11.65 - $12.35, versus consensus of $11.93.
- The company said it performed an average of 83,000 COVID-19 Molecular Tests a day in Q3.
- Related Link: Quest Diagnostics Updates 2021 Outlook On Surging Demand Of COVID-19 Tests.
- Price Action: DGX shares are up 2.35% at $150.03 during the premarket session on the last check Thursday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in